QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:SNY

Sanofi - SNY Stock Forecast, Price & News

$41.19
-0.99 (-2.35%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$40.92
$41.54
50-Day Range
$41.19
$51.60
52-Week Range
$40.92
$58.10
Volume
4.30 million shs
Average Volume
2.38 million shs
Market Capitalization
$104.25 billion
P/E Ratio
13.68
Dividend Yield
2.99%
Price Target
$111.14

Sanofi MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
169.8% Upside
$111.14 Price Target
Short Interest
Healthy
0.11% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.10mentions of Sanofi in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
3.64%
From $4.12 to $4.27 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

292nd out of 1,119 stocks

Pharmaceutical Preparations Industry

133rd out of 549 stocks

SNY stock logo

About Sanofi (NASDAQ:SNY) Stock

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Analyst Ratings Changes

Several research firms recently weighed in on SNY. StockNews.com raised Sanofi from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Credit Suisse Group lifted their price target on Sanofi from €105.00 ($107.14) to €110.00 ($112.24) and gave the stock an "outperform" rating in a research note on Friday, July 22nd. UBS Group cut shares of Sanofi from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 9th. JPMorgan Chase & Co. lifted their target price on shares of Sanofi from €105.00 ($107.14) to €115.00 ($117.35) in a research report on Monday, August 1st. Finally, Morgan Stanley increased their price target on shares of Sanofi from €110.00 ($112.24) to €112.00 ($114.29) in a research report on Friday, April 22nd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $111.14.

Sanofi Stock Performance

Shares of SNY opened at $42.18 on Thursday. Sanofi has a 1 year low of $41.29 and a 1 year high of $58.10. The company's 50 day simple moving average is $48.92 and its 200 day simple moving average is $50.91. The company has a market capitalization of $106.75 billion, a price-to-earnings ratio of 14.01, a PEG ratio of 1.05 and a beta of 0.48. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.34 and a current ratio of 1.29.

Sanofi (NASDAQ:SNY - Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.07. The company had revenue of $10.78 billion for the quarter, compared to analyst estimates of $10.32 billion. Sanofi had a return on equity of 25.99% and a net margin of 16.60%. On average, sell-side analysts predict that Sanofi will post 4.12 EPS for the current year.

Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Stock News Headlines

Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.
Sanofi (NASDAQ:SNY) Lifted to "Strong-Buy" at StockNews.com
Sanofi (NASDAQ:SNY) Upgraded at Deutsche Bank Aktiengesellschaft
GSK, Sanofi in selloff extending Novavax-led rout
Sanofi (NASDAQ:SNY) Downgraded by UBS Group to Neutral
See More Headlines
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Company Calendar

Ex-Dividend for 6/8 Dividend
5/04/2022
Dividend Payable
6/08/2022
Last Earnings
7/28/2022
Today
8/18/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNY
Employees
95,442
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$111.14
High Stock Price Forecast
$127.00
Low Stock Price Forecast
$90.00
Forecasted Upside/Downside
+169.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$7.36 billion
Pretax Margin
19.91%

Debt

Sales & Book Value

Annual Sales
$44.68 billion
Cash Flow
$4.99 per share
Book Value
$29.98 per share

Miscellaneous

Outstanding Shares
2,530,864,000
Free Float
2,505,555,000
Market Cap
$104.25 billion
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Mr. Paul HudsonMr. Paul Hudson (Age 55)
    CEO & Director
    Comp: $5.74M
  • Mr. Jean-Baptiste Chasseloup de ChatillonMr. Jean-Baptiste Chasseloup de Chatillon (Age 57)
    Exec. VP & CFO
  • Mr. Laurent Gilhodes
    Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard
    Chief Information officer
  • Dr. Josephine Fubara
    Chief Science Officer of Consumer Health Care
  • Eva Schaefer-Jansen
    Head of Investor Relations
  • Mr. Dante Beccaria
    Global Compliance Officer & VP
  • Mr. Roy Papatheodorou (Age 44)
    Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity
  • Mr. Josep Catlla
    Head of Communications
  • Mr. Pierre Chancel (Age 65)
    Sr. VP of Global Diabetes and Sr. VP of Global Marketing













SNY Stock - Frequently Asked Questions

Should I buy or sell Sanofi stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNY shares.
View SNY analyst ratings
or view top-rated stocks.

What is Sanofi's stock price forecast for 2022?

8 analysts have issued 1 year price targets for Sanofi's shares. Their SNY share price forecasts range from $90.00 to $127.00. On average, they anticipate the company's stock price to reach $111.14 in the next year. This suggests a possible upside of 169.8% from the stock's current price.
View analysts price targets for SNY
or view top-rated stocks among Wall Street analysts.

How have SNY shares performed in 2022?

Sanofi's stock was trading at $50.10 on January 1st, 2022. Since then, SNY shares have decreased by 17.8% and is now trading at $41.19.
View the best growth stocks for 2022 here
.

When is Sanofi's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our SNY earnings forecast
.

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) announced its earnings results on Thursday, July, 28th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.07. The company earned $10.78 billion during the quarter, compared to analysts' expectations of $10.32 billion. Sanofi had a net margin of 16.60% and a trailing twelve-month return on equity of 25.99%.

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Friday, April 22nd. Investors of record on Thursday, May 5th will be given a dividend of $1.7968 per share on Wednesday, June 8th. This represents a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, May 4th.
Read our dividend analysis for SNY
.

Is Sanofi a good dividend stock?

Sanofi (NASDAQ:SNY) pays an annual dividend of $1.26 per share and currently has a dividend yield of 2.99%. The dividend payout ratio is 41.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 29.51% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SNY.

What guidance has Sanofi issued on next quarter's earnings?

Sanofi issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $8.04-$8.04 for the period. The company issued revenue guidance of -.

What is Paul Hudson's approval rating as Sanofi's CEO?

277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).

What is Sanofi's stock symbol?

Sanofi trades on the NASDAQ under the ticker symbol "SNY."

Who are Sanofi's major shareholders?

Sanofi's stock is owned by many different retail and institutional investors. Top institutional investors include Dodge & Cox (3.04%), FMR LLC (0.74%), Price T Rowe Associates Inc. MD (0.68%), Lazard Asset Management LLC (0.12%), Goldman Sachs Group Inc. (0.10%) and Macquarie Group Ltd. (0.10%).
View institutional ownership trends
.

How do I buy shares of Sanofi?

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $41.19.

How much money does Sanofi make?

Sanofi (NASDAQ:SNY) has a market capitalization of $104.25 billion and generates $44.68 billion in revenue each year. The company earns $7.36 billion in net income (profit) each year or $3.01 on an earnings per share basis.

How many employees does Sanofi have?

The company employs 95,442 workers across the globe.

Does Sanofi have any subsidiaries?
The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..
Read More
When was Sanofi founded?

Sanofi was founded in 2004.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The official website for the company is www.sanofi.com. The company can be reached via phone at (315) 377-4000, via email at ir@sanofi.com, or via fax at 33-1-53-77-43-03.

This page (NASDAQ:SNY) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.